Japan Prescription Digital Therapeutics (PDTx) Market Summary:
According to Transpire Insights, a detailed research report on the market reflects that the Diabetes segment dominates the Japan Prescription Digital Therapeutics (PDTx) Market, accounting for approximately 40% of the total market share in 2025. The Digital CBT segment follows with approximately 26% market share, while the Smartphone Apps segment leads the delivery model with approximately 79% share in 2025, making these segments key contributors to Japan market development, innovation, digital healthcare adoption, advanced prescription digital therapeutics solutions, expanding healthcare capabilities, and overall market growth dynamics.
Market Snapshot
- Market Value (2025): USD 0.40 Billion.
- Expected Market Value (2026): USD 0.46 Billion.
- Estimated Market Value (2033): USD 1.28 Billion.
- Forecast CAGR (2026–2033): 15.74%.
Introduction
The Japan Prescription Digital Therapeutics (PDTx) Market includes software-based medical interventions that are clinically validated, prescribed by healthcare professionals and are used to prevent, manage or treat specific medical conditions. Such solutions are generally regulated as Software as a Medical Device (SaMD) under Japan’s pharmaceutical and medical device framework and require evidence to prove safety, efficacy and therapeutic benefit. Japan’s DTx ecosystem consists of prescription therapeutic apps, digital cognitive behavioral therapy, behavioral modification programs, and connected digital interventions for disease management. Growing adoption in the market is due to increased incorporation of digital healthcare into clinical practice and Japan’s organized regulatory pathway & national health insurance ecosystem. Key application areas are diabetes and metabolic disorders, nicotine dependence, mental and neurological conditions, cardiovascular diseases, respiratory disorders, and chronic disease management. This creates opportunities for technology developers and healthcare providers.
Key Market Highlights: -
- By Therapeutic Area, the Diabetes segment dominated the market and holds approximately 40% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
- By Product Type, the Digital CBT segment dominated the market and holds approximately 26% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
- By Delivery Model, the smartphone apps Manufacturers segment dominated the market and holds approximately 79% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
- Regulatory and Reimbursement Support: The structured approval pathway in Japan (PMDA–MHLW) and the national health insurance framework enhance clinical adoption, market access, reimbursement potential, and commercialization opportunities for prescription digital therapeutics.
How is Technology Driving Growth in the Japan Prescription Digital Therapeutics (PDTx) Market?
Technology is a major growth driver in the Japan Prescription Digital Therapeutics (PDTx) Market, providing clinically validated digital interventions via smartphones, connected devices, remote monitoring and artificial intelligence. Smartphone-based therapeutic applications support ongoing patient engagement, treatment adherence, behavioral change, and disease management outside traditional clinical settings. Integration with wearable sensors could allow for remote collection of relevant physiological and behavioral data, allowing for customized treatment and healthcare-provider surveillance. Artificial intelligence may improve data analysis and adaptive therapeutic approaches further, and virtual reality is an increasingly complementary platform for digital interventions. These technological advances are also advancing the scalability, personalization and clinical integration of prescription digital therapeutics in Japan, especially in chronic disease and behavioral health uses.
Market Drivers
The Japan Prescription Digital Therapeutics (PDTx) Market is picking up momentum as healthcare providers, technology companies and pharmaceutical companies increasingly adopt clinically validated digital interventions. Aging demographics and increasing rates of chronic diseases such as diabetes, hypertension, and behavioral health conditions are driving demand for scalable disease-management solutions. The evolving regulatory landscape in Japan under the PMD Act offers a pathway to classify and assess eligible digital therapeutics as Software as a Medical Device (SaMD) and provides a structured pathway for clinical validation and market authorization. Reimbursement for eligible prescription digital therapeutics from national health insurance could further increase patient access and healthcare provider uptake. Moreover, strategic alliances between pharma and tech companies are accelerating the product development, clinical validation, commercialization and integration of digital therapeutics into Japan’s healthcare ecosystem.
Restrain
There are several adoption barriers for the Japan Prescription Digital Therapeutics (PDTx) Market, such as stringent evidence and reimbursement requirements, which can increase the complexity of commercialization. High costs of clinical validation, regulatory compliance, software development and generating post-market evidence can put pressure on developers. Limited familiarity among some healthcare professionals with prescription digital therapeutics may slow clinical adoption. Additionally, usability challenges with older patients, and strict data privacy and cybersecurity requirements, could complicate implementation, integration, and long-term patient engagement.
Analysis of Prices and Consumer Behaviour
The Japan Prescription Digital Therapeutics (PDTx) market is driven by a growing pipeline of clinically validated digital therapies, with 35 DTx products in development as of June 2026, primarily focused on chronic and behavioral health conditions. The Japanese DTx ecosystem consists of prescription-based software applications, connected-device interventions and digitally delivered therapeutic programs that are supported by clinical evidence and regulatory oversight. The commercial pathway for reimbursed digital therapeutics was improved when the national health insurance approved two DTx products for coverage in June 2026. The market is driven by applications for diabetes, hypertension, smoking cessation, insomnia, mental health, cardiovascular and respiratory diseases. As pharmaceutical companies, technology firms, healthcare institutions, and academic organisations continue to expand Japan’s DTx development pipeline, purchasing & adoption decisions are increasingly focused on clinical efficacy, patient engagement, usability, data security, reimbursement eligibility, and integration with healthcare-provider workflows.
Top Companies in the Japan Prescription Digital Therapeutics (PDTx) Market
- CureApp
- Otsuka Pharmaceutical
- Jolly Good
- Welldoc
- Akili Interactive
- Omada Health
- DarioHealth
- Biofourmis
- Teladoc Health
- ResMed
- Medtronic
- Philips
- M3
- NTT Data
- Medley
Japan Prescription Digital Therapeutics (PDTx) Market Segmentation
The Japan Prescription Digital Therapeutics (PDTx) Market share is divided into six categories: By Therapeutic Area, By Product Type, By Delivery Model, By Patient Type, By End User, and By Business Model.
The Diabetes dominated the market, accounting for nearly 40% in 2025 and is expected to rise at a significant CAGR during the forecast period.
The Japan Prescription Digital Therapeutics (PDTx) Market is segmented by therapeutic area into diabetes, hypertension, obesity, smoking cessation, mental health, neurological disorders, cardiovascular diseases, respiratory diseases. Among these, the Diabetes segment dominated the market, accounting for nearly 40% in 2025 and expected to increase at a significant CAGR during the forecast period. The Japan Prescription Digital Therapeutics (PDTx) Market was dominated by the Diabetes segment, which held a share of nearly 40% in 2025 due to the increasing prevalence of chronic diseases, the need for ongoing surveillance, and increasing adoption of digital diabetes management solutions.
The Digital CBT dominated the market, accounting for nearly 26% in 2025, and is expected to rise at a significant CAGR during the forecast period.
The Japan Prescription Digital Therapeutics (PDTx) Market is segmented by product type into prescription apps, digital cbt, disease management platforms, behavioral therapy apps, medication-adherence platforms, digital rehabilitation, remote monitoring-based dtx, ai-enabled dtx. Among these, the Digital CBT segment dominated the market, accounting for nearly 26% in 2025 and expected to increase at a significant CAGR during the forecast period. The Digital CBT segment held the largest share of the Japan Prescription Digital Therapeutics (PDTx) Market, contributing to nearly 26% in 2025, owing to the increasing demand for evidence-based behavioural interventions & insomnia and mental-health management.
The smartphone apps dominated the market, accounting for nearly 79% in 2025 and is expected to rise at a significant CAGR during the forecast period.
The Japan Prescription Digital Therapeutics (PDTx) Market is segmented by delivery model into smartphone apps, tablet-based platforms, web-based platforms, connected devices, wearable-integrated systems, cloud platforms, hybrid digital-physical therapy, ai-based platforms. Among these, the smartphone apps segment dominated the market, accounting for nearly 79% in 2025 and expected to increase at a significant CAGR during the forecast period. The smartphone apps segment led the Japan Prescription Digital Therapeutics (PDTx) Market with a share of more than 79% in 2025 owing to ease of availability, ease of home-based therapy, & seamless patient engagement.
Future Market Trends for the Japan Prescription Digital Therapeutics (PDTx) Market: -
- Strategic Co-Development: More partnerships between pharma and digital health companies to co-develop, validate, commercialise and scale prescription digital therapeutics across Japan.
- Broader therapeutic growth. Future PDTx development in Japan will increasingly target cardiovascular, neurological, metabolic, behavioural, and chronic disease management with clinically validated digital interventions.
- AI-Enabled Personalisation: AI, in conjunction with connected wearables and remote monitoring, will augment personalised treatment, continuous patient engagement, behavioural interventions, and healthcare provider decision support.
Recent Development
In June 2026, Yano Research Institute reported that two approved SaMD products were covered by Japan’s National Health Insurance, which strengthens the commercialisation and market access for prescription digital therapeutics.
In August 2026: Yano Research Institute reported 35 DTx products in clinical development in Japan, with rising innovation in metabolic, neurological, mental health, and oncology applications.
Market Segment
This study forecasts revenue at Japan, regional and country levels from 2020 to 2033. Transpire Insights has segmented the Japan Prescription Digital Therapeutics (PDTx) Market based on the below-mentioned segments:
Japan Prescription Digital Therapeutics (PDTx) Market, By Therapeutic Area
- Diabetes
- Hypertension
- Obesity
- Smoking Cessation
- Mental Health
- Neurological Disorders
- Cardiovascular Diseases
- Respiratory Diseases
Japan Prescription Digital Therapeutics (PDTx) Market, By Product Type
- Prescription Apps
- Digital CBT
- Disease Management Platforms
- Behavioral Therapy Apps
- Medication-Adherence Platforms
- Digital Rehabilitation
- Remote Monitoring-Based DTx
- AI-Enabled DTx
Japan Prescription Digital Therapeutics (PDTx) Market, By Delivery Model
- Smartphone Apps
- Tablet-Based Platforms
- Web-Based Platforms
- Connected Devices
- Wearable-Integrated Systems
- Cloud Platforms
- Hybrid Digital-Physical Therapy
- AI-Based Platforms
Japan Prescription Digital Therapeutics (PDTx) Market, By Patient Type
- Adults
- Elderly Patients
- Pediatric Patients
- Chronic Disease Patients
- Mental Health Patients
- Cardiovascular Patients
- Metabolic Disease Patients
- Rehabilitation Patients
Japan Prescription Digital Therapeutics (PDTx) Market, By End User
- Patients
- Hospitals
- Physicians
- Specialty Clinics
- Pharmacies
- Health Insurance Providers
- Corporate Healthcare Programs
- Home Healthcare
Japan Prescription Digital Therapeutics (PDTx) Market, By Business Model
- Prescription-Based
- Insurance-Reimbursed
- Hospital-Prescribed
- Physician-Prescribed
- Employer-Sponsored
- Self-Pay
- Subscription
- Hybrid Reimbursement
Frequently Asked Questions
Find quick answers to common questions.
Aging demographics, chronic disease prevalence, digital healthcare adoption, reimbursement opportunities, and pharmaceutical-technology partnerships are accelerating Japan’s PDTx market growth
Diabetes dominates the market, supported by rising chronic disease management needs, continuous monitoring requirements, and growing adoption of digital therapeutic solutions.
Digital CBT benefits from increasing demand for evidence-based behavioral interventions addressing insomnia, mental health conditions, treatment adherence, and accessible therapeutic support.
Smartphone applications, artificial intelligence, wearable integration, and remote monitoring enable personalized treatment, continuous engagement, data-driven interventions, and improved chronic disease management.
Stringent clinical evidence requirements, reimbursement complexity, development costs, physician adoption barriers, cybersecurity concerns, and usability challenges can restrict market expansion
- CureApp
- Otsuka Pharmaceutical
- Jolly Good
- Welldoc
- Akili Interactive
- Omada Health
- DarioHealth
- Biofourmis
- Teladoc Health
- ResMed
- Medtronic
- Philips
- M3
- NTT Data
- Medley
About the Authors
Pankaj Ghogare Patil
I am Pankaj Ghogare Patil, a Senior Research Analyst at Transpire Insight, specializing in the Pharmaceutical, Chemicals & Materials, Healthcare IT, and Biotechnology industry. My expertise lies in conducting comprehensive market research, analyzing industry trends, evaluating competitive landscapes, and translating complex data into actionable insights. At Transpire Insight, I closely follow emerging technologies, regulatory developments, and market innovations to create accurate, well-researched, and informative content that helps businesses and professionals make informed decisions. I am committed to producing credible, evidence-based articles that reflect industry best practices while making technical topics accessible and valuable for a broad audience.
Chakradhar Khansole
Chakradhar serves as the Research Director at Transpire Insight, bringing over 8 years of experience in technology, innovation, and strategic market intelligence. He specializes in transforming complex market data into actionable business insights that enable organizations to make informed, growth-oriented decisions. Recognized for his strategic vision and analytical expertise, Chakradhar leads high-impact research initiatives, delivering comprehensive market assessments, competitive intelligence, and forward-looking industry analysis.
Recently Published Reports
-
Apr 2026
AI in Diabetic Retinopathy Market
AI in Diabetic Retinopathy Market Size, Share & Analysis Report By Type (Screening AI Systems, Diagnostic AI Systems, and Predictive AI Models), By Application Segment (Hospitals, Ophthalmology Clinics, Diagnostic Centers, and Research and Development), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America), 2021 - 2031
-
Apr 2026
Psychometric Tests Market
Psychometric Tests Market Size, Share & Analysis Report By Type (Personality Tests, Ability/Aptitude Tests, Skill/Knowledge Tests, and Others), By Application (Talent Acquisition and Talent Management), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America), 2021 – 2031
-
Apr 2026
Rare Biological Sample Collection Market
Rare Biological Sample Collection Market Size, Share & Analysis Report By Type (Isolation Kits & Reagent, Blood Collection Tubes, and Others), By Application (Oncology, Transcriptomics, Pharmacogenomics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America), 2021 – 2031
-
Jul 2026
Diabetic Retinopathy Market
Diabetic Retinopathy Market Size, Share & Analysis Report By Type (Proliferative Diabetic Retinopathy, and Diabetic Macular Edema (DME)), By Treatment Type (Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America), 2021 – 2031
Our Clients
.jpg){kind=logo}
